Long-term Risk of Recurrent Venous Thromboembolism Among Patients Receiving Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism.

Khan, Faizan; Tritschler, Tobias; Kimpton, Miriam; Wells, Philip S; Kearon, Clive; Weitz, Jeffrey I; Büller, Harry R; Raskob, Gary E; Ageno, Walter; Couturaud, Francis; Prandoni, Paolo; Palareti, Gualtiero; Legnani, Cristina; Kyrle, Paul A; Eichinger, Sabine; Eischer, Lisbeth; Becattini, Cecilia; Agnelli, Giancarlo; Vedovati, Maria Cristina; Geersing, Geert-Jan; ... (2021). Long-term Risk of Recurrent Venous Thromboembolism Among Patients Receiving Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. Journal of thrombosis and haemostasis, 19(11), pp. 2801-2813. Wiley-Blackwell 10.1111/jth.15491

Preview

Text Tritschler__J_Thromb_Haemost_2021.pdf - Accepted Version Available under License Publisher holds Copyright. Download (13MB) | Preview

BACKGROUND

The long-term risk for recurrent venous thromboembolism (VTE) during extended anticoagulation for a first unprovoked VTE is uncertain.

OBJECTIVES

To determine the incidence of recurrent VTE during extended anticoagulation up to 5 years in patients with a first unprovoked VTE.

METHODS

MEDLINE, EMBASE, and the Cochrane CENTRAL were searched to identify randomized trials and prospective cohort studies reporting recurrent VTE among patients with a first unprovoked VTE who were to receive anticoagulation for a minimum of 6 additional months after completing ≥ 3 months of initial treatment. Unpublished data on number of recurrent VTE and person-years, obtained from authors of included studies, were used to calculate study-level incidence rate, and random-effects meta-analysis was used to pool results.

RESULTS

Twenty-six studies and 15, 603 patients were included in the analysis. During 11, 631 person-years of follow-up, the incidence of recurrent VTE and fatal pulmonary embolism per 100 person-years was 1.41 (95% CI, 1.03-1.84) and 0.09 (0.04-0.16), with 5-year cumulative incidences of 7.1% (3.0%-13.2%) and 1.2% (0.4%-4.6%), respectively. The incidence of recurrent VTE was 1.08 (95% CI, 0.77-1.44) with direct oral anticoagulants and 1.55 (1.01-2.20) with vitamin K antagonists. The case-fatality rate of recurrent VTE was 4.9% (95% CI, 2.2%-8.7%).

CONCLUSIONS

In patients with a first unprovoked VTE, the long-term risk of recurrent VTE during extended anticoagulation is low but not negligible. Thus, clinicians and patients should be aware of this risk and take appropriate and timely action in case of suspicion of recurrent VTE. Estimates from this study can be used to advise patients on what to expect while receiving extended anticoagulation, and estimate the net clinical benefit of extended treatment to guide long-term management of unprovoked VTE.

Interest & Impact

Downloads

107 since deposited on 07 Sep 2021
107 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item